Researchers plan to begin the first patient trial in 2027 thanks to promising preclinical results from a gene therapy ...

A single injection of a redesigned immune-stimulating antibody directly into a tumor was linked to shrinkage not only at the ...

Data presented by Johnson & Johnson at the 2026 European Lung Cancer Conference PARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company” ...

The MarketWatch News Department was not involved in the creation of this content.-- Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equiv ...

Alpha Tau Medical (NASDAQ:DRTS) provided investors with a series of clinical, regulatory and financial updates, highlighting ...

Solid tumors are heterogeneous with an immunosuppressive tumor microenvironment, but that is not slowing the search to treat the most difficult, recalcitrant cases ...

Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets ...

Data was published in the Online Itinerary Planner for the 2026 AACR Annual Meeting, and is scheduled to be presented at the meeting on April 19thGARDEN CITY, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- ...

Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...

Combination therapy led to complete remission in more than 50% of mice with different tumor types, many of which were resistant to ICB therapy alone.

Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, ...